Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651976 · ClinicalTrials.gov registry record · Early Phase 1
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
A Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 213
- Enrollment target
NCT00651976: Clinical Trial Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00651976 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 213 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (302% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00651976, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
RATIONALE: Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery allows us to monitor the effects of letrozole on the tumor on a molecular level and determine markers of response to treatment. PURPOSE: This study will show us how well letrozole works in treating postmenopausal women with stage I, II or III breast cancer that can be removed by surgery.
Primary Outcome
Ki67 index is measured by counting the percentage of cells staining for Ki67 in a section of breast tissue. The number of stained cells will be compared in tissue that is hormone receptor-positive tissue to tissue that is hormone receptor negative.
Interventions
- OTHER Blood Collection
- DRUG letrozole
- PROCEDURE biopsy/lumpectomy/mastectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2008-03 |
| Est. Completion | 2018-09 |
| Phase | Early Phase 1 |
Why NCT00651976 stopped before completion
NCT00651976 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (302% higher).
The record links to 0 conditions, and to 3 interventions - of which Blood Collection is the first listed.
NCT00651976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00651976 about?
NCT00651976 is a clinical study titled "Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery". RATIONALE: Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery allows us to monitor the effects of letrozole on the tumor on a molecular level and determine markers of response to treatment. PURPOSE: This study w...
What is the current status of trial NCT00651976?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 213 participants. The study started on 2008-03. Estimated completion is 2018-09.
What interventions are being tested in trial NCT00651976?
The interventions under investigation include: Blood Collection (OTHER), letrozole (DRUG), biopsy/lumpectomy/mastectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00651976?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00651976's enrollment target sits among peer trials
213 58th of 2000 higher than 1,943 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia